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trans-Resveratrol inhibits calcium in¯ux in thrombin-stimulated
human platelets
1

Yuliya Dobrydneva, 1Roy L. Williams & *,2Peter F. Blackmore

1

Department of Chemistry and Biochemistry, Old Dominion University, Norfolk, Virginia, VA 23501, U.S.A., and 2Department of
Physiological Sciences, Eastern Virginia Medical School, PO Box 1980, Norfolk, Virginia, VA 23501-1980, U.S.A.
1 The phytoestrogenic compound trans-resveratrol (trans-3,5,4'-trihydroxystilbene) is found in
appreciable quantities in grape skins and wine. It has been shown that both products rich in transresveratrol and pure trans-resveratrol inhibit platelet aggregation both in vivo and in vitro. However
the mechanism of this action still remains unknown.
2 An essential component of the aggregation process in platelets is an increase in intracellular free
Ca2+ ([Ca2+]i). Ca2+ must enter the cell from the external media through speci®c and tightly
regulated Ca2+ channels in the plasma membrane. The objective of this study was to characterize
what eect trans-resveratrol had on the Ca2+ channels in thrombin stimulated platelets.
3 In this study we showed that trans-resveratrol immediately inhibited Ca2+ in¯ux in thrombinstimulated platelets with an IC50 of 0.5 mM. trans-Resveratrol at 0.1, 1.0 and 10.0 mM produced
20+6, 37+6 and 57+4% inhibition respectively of the eect of thrombin (0.01 u ml71) to increase
[Ca2+]i.
4 trans-Resveratrol also inhibited spontaneous Ba2+ entry into Fura-2 loaded platelets, with 0.1,
1.0 and 10.0 mM trans-resveratrol producing 10+5, 30+5 and 50+7% inhibition respectively. This
indicated that trans-resveratrol directly inhibited Ca2+ channel activity in the platelets in the absence
of agonist stimulation.
5 trans-Resveratrol also inhibited thapsigargin-mediated Ca2+ in¯ux into platelets. This suggests
that the store-operated Ca2+ channels are one of the possible targets of trans-resveratrol. These
channels rely on the emptying of the internal Ca2+ stores to initiate in¯ux of Ca2+ into the cell.
6 The phytoestrogens genistein, daidzein, apigenin and genistein-glucoside (genistin) produced
inhibitory eects against thrombin similar to those seen with trans-resveratrol.
7 We conclude that trans-resveratrol is an inhibitor of store-operated Ca2+ channels in human
platelets. This accounts for the ability of trans-resveratrol to inhibit platelet aggregation induced by
thrombin.
Keywords: trans-Resveratrol; platelets; aggregation; calcium; barium; channels; thapsigargin; phytoestrogen; thrombosis;
thrombin

Abbreviations: ADP, adenosine diphosphate; [Ca2+]i, intracellular free calcium; EGTA, ethylene glycol bis(b-aminoethyl ether)
N,N,N',N'-tetraacetic acid; IP3, myo-inositol 1,4,5-trisphosphate; Me2SO, dimethylsulphoxide; RMCE, receptormediated calcium entry; ROC, receptor-operated channel; SMOC, second messenger operated channel; SOCC,
store operated calcium channel

Introduction
Platelets, the major hemostatic cell in blood, are formed in the
bone marrow from the precursor cell megacaryocytes (Heyns,
1994). Structurally, platelets contain no nucleus and have a
large number of granules (dense granules and a-granules) for
the storage of biologically active compounds such as serotonin,
ADP and platelet derived growth factor (White, 1994). The
contents of the granules are released upon platelet activation.
The intracellular dense tubular system (analogous to the
endoplasmic reticulum) serves as a calcium storage site
(Crawford & Scrutton, 1994).
Platelets are activated by multiple factors (agonists)
produced at the site of vascular injury (Brass et al., 1993;
Hourani & Cusack, 1991). These factors include ADP,
collagen, thromboxane A2 and thrombin, the most potent
platelet activator. Upon activation, platelets undergo shape
change, express ®brinogen receptors, aggregate and release
their granule contents. As a result a hemostatic plug is formed
on a ®brin meshwork thus sealing the damaged blood vessel.

*Author for correspondence; E-mail: blackmore@evms.edu

Excessive platelet aggregation however plays a role in the
development of thrombosis and therefore it is important that
this process is properly regulated for the ecient functioning
of the cardiovascular system.
The major intracellular stimulus involved in platelet
aggregation is an increase in free cytosolic calcium concentration ([Ca2+]i) (Sage & Rink, 1990). As in most non-excitable
cells the increase in platelet [Ca2+]i induced by various agonists
involves both in¯ux of extracellular calcium through plasma
membrane calcium channels and mobilization of intracellular
calcium from the dense tubular system (Berridge, 1997;
Heemskerk & Sage, 1994; Sage, 1997).
The pathway(s) of the calcium entry in platelets share
common properties with the calcium entry pathways found in
other non-excitable cells. The mechanism of calcium release
from the myo-inositol 1,4,5-P3 (IP3)-sensitive internal stores is
well characterized. On the other hand, the mechanism of the
calcium in¯ux pathway in platelets is still not completely
resolved (Sage, 1997). Calcium from the external medium
enters the cell through speci®c ion channels of several dierent
types. Platelets, according to Sage (1997), lack voltage-gated
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calcium channels, so the change in the membrane potential
does not generate calcium in¯ux, and platelets are reported not
to bind verapamil and nifedipine. Instead, receptor-mediated
calcium entry (RMCE) through the plasma membrane channel
following binding of a ligand to its membrane receptor seems
to be responsible for calcium in¯ux into platelets. RMCE
channels may be one of the following types: ROC (receptoroperated channel), SMOC (second messenger operated
channel) and SOCC (store-operating calcium channel) (Sage,
1997). SOCC channels are activated to promote calcium in¯ux
upon the emptying of the internal calcium stores (dense
tubular system). The mechanism which links the depletion of
the IP3-sensitive internal calcium stores to the SOCC have not
yet been elucidated (Parekh & Penner, 1997; Clementi &
Meldolesi, 1996). There are currently two models proposed for
activating SOCC: (1) the two kinds of channels (plasma
membrane calcium channel and the intracellular endoplasmic
reticulum IP3 sensitive calcium channel) are coupled to each
other by physical proximity or (2) the emptying of the internal
stores generates a calcium in¯ux factor (CIF), which then acts
on the plasma membrane calcium channels. The speci®c nature
of CIF is poorly de®ned, however it may involve arachidonate
metabolites and S-nitrosylation (e.g. Rzigalinski et al., 1996;
1999; Favre et al., 1998).
A very important tool used to study SOCC is a plant
derived tumor promoter known as thapsigargin (Thastrup et
al., 1990). Thapsigargin eectively inhibits the calcium ATPase
pump of the endoplasmic reticulum without increasing the
level of IP3. When the pump is inhibited, calcium is prevented
from entering the intracellular stores. Stored calcium leaks into
the cytoplasm, some of which is extruded from the cell by the
plasma membrane Ca2+-ATPase pump. Consequently, store
emptying evokes calcium in¯ux through SOCC in the plasma
membrane (Parekh & Penner, 1997).
It has been reported numerous times that consumption of
certain foods, grapes and red wine, serve as a protective factor
against coronary heart disease (CHD). The `French paradox'
correlates the lower prevalence of CHD with the regular
moderate consumption of red wine (Soleas et al., 1997). The
bene®cial eects of this product have been attributed to their
high antioxidant/phytoestrogenic content (e.g. Miksicek, 1995;
Williams & Rutledge, 1998).
Phytoestrogens are naturally occurring antioxidant compounds, usually polyphenols, which are present in the variety
of foods and beverages. Phytoestrogens derived their name for
their ability to mimic the actions of oestrogens (female sex
hormones). They can bind to the human oestrogen receptor
and activate genomic oestrogen-response elements, although at
a much higher concentration than the natural oestrogens
(Miksicek, 1995; Gehm et al., 1997). trans-Resveratrol (trans3,5,4'-trihydroxystilbene) (Figure 1) is a phytoestrogenic
compound found in grapes (Miksicek, 1995), it possesses
antitumor, antioxidative and antifungal activities (Jang et al.,
1997; Tham et al 1998).
trans-Resveratrol inhibits human platelet aggregation both
in vitro and in vivo (Pace-Asciak et al., 1995; 1996; Bertelli et
al., 1995). This has important implications in ascribing how the
intake of phytoestrogens in food can help prevent thrombosis,
essentially serving as a blood thinner, having potentially
bene®cial eects on the cardiovascular system. However, the
mechanism by which trans-resveratrol inhibits platelet
aggregation has not been elucidated. Since aggregation can
not occur without a sucient increase in the [Ca2+]i, the goal
of the present study was to establish if dietary phytoestrogens,
such as trans-resveratrol, could have an eect on the calcium
channels in stimulated human platelets.

trans-Resveratrol inhibits platelet Ca2+ influx

Phytoestrogenic iso¯avonoids genistein and daidzein and
the ¯avonoid apigenin (Figure 1) are also encountered in foods
such as soy beans and were also examined brie¯y in this study.
Genistein is also known as a potent tyrosine kinase inhibitor
(Jayatilake et al., 1993), and is also known to inhibit certain
tumor cell growth (e.g. Fioravanti et al., 1998). Previous
studies have shown that 100 mM genistein but not daidzein was
able to inhibit ADP and thrombin induced calcium in¯ux in
human platelets (Sargeant et al., 1993a,b), it was concluded
that tyrosine phosphorylation controlled calcium entry. Our
®ndings are more consistent with genistein and daidzein having
a more direct eect on calcium channels.

Methods
Reagents and material sources
The following were from Sigma Chemical Co: trans-resveratrol, apigenin (4',5,7-trihydroxy¯avone), genistein (4',5,7trihydroxyiso¯avone), genistein-7-O-D-glucoside (genistin),
daidzein (4',7-dihydroxyiso¯avone), thrombin, Me2SO (dimethylsulphoxide) and EGTA [ethylene glycol-bis(b-aminoethyl ether)N,N,N',N'-tetraacetic acid]. The following were
from Calbiochem: thapsigargin and ionomycin. Fura-2 A/M
was from Molecular Probes. Other chemicals were from Fisher
Scienti®c and Sigma Chemical Co.

Figure 1 Structures of the phytoestrogens
genistein, apigenin and daidzein.

trans-resveratrol,
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Blood donors and platelet preparation

Platelet loading with fura-2 and measurement of [Ca2+]i

All donors were healthy volunteers (aged 20 ± 40 years) who
had not consumed any medication known to aect platelet
function (e.g. calcium channel blockers and aspirin) for at
least 10 days prior to the study. Venous blood was collected
into 1/10 volume of ACD (74.8 mM sodium citrate, 38.1 mM
citric acid and 123 mM dextrose pH 6.4) (Baxter Healthcare
Corp.). The blood was centrifuged at 2506g for 10 min at
room temperature to obtain platelet rich plasma (PRP). The
PRP was centrifuged at 5506g for 12 min to sediment the
platelets. The platelets were then re-suspended in a modi®ed
Tyrodes physiological salt solution (in mM): NaCl 145, KCl
4, MgSO4 1, Na2HPO4 0.5, Na/HEPES 10, glucose 6,
pH 7.4, containing 1.0 mM EGTA which acted to prevent
spontaneous aggregation during the various experimental
manipulations by binding extracellular Ca2+ (Nolan &
Lapetina, 1990). The platelets were washed once (5006g
for 15 min) and ®nally re-suspended at a count of
approximately 36108 platelets ml71.

Intracellular calcium measurements [Ca2+]i employed the
¯uorescent dye fura-2, which involved incubating the platelets
with the cell permeant acetoxymethyl ester (fura-2/AM) (e.g.
Sargeant et al., 1992). A suspension of human platelets
(isolated as described above) was incubated with 2 mM fura2/AM for 1 h at room temperature (on a rocking platform).
Excess fura-2/AM was removed by centrifugation (5006g for
10 min) and the platelets suspended in fresh buer, without
added EGTA. Aliquots of platelet suspension (0.5 ml) were
added to 1.0 ml cuvettes containing a Te¯on coated stirrer bar
(Chrono-log, Havertown, PA, U.S.A.). Just before [Ca2+]i
measurements were performed, Ca2+ was added back to the
buer to a ®nal concentration of 2 mM, then phytoestrogens
(various concentrations in 2.5 ml) and thrombin 0.01 u ml71
were added (see individual Figure legends for speci®c details).
The eects of trans-resveratrol and other phytoestrogens to
inhibit the actions of thrombin (see Results) were immediate.
In preliminary experiments we added trans-resveratrol
together with thrombin and the inhibitory eect was the same
as if we preincubated the trans-resveratrol for 5 ± 10 s or
120 min before thrombin. trans-Resveratrol therefore produced an immediate blockade of calcium in¯ux channel. Also
when trans-resveratrol was added 60 s after thrombin, the
[Ca2+]i declined immediately to a value approaching the
inhibitory eect observed when trans-resveratrol was added
just prior to the addition of thrombin. The measurements of
[Ca2+]i were performed at room temperature in a SPEX

Phytoestrogen solution preparations
Stock solutions of the phytoestrogens (trans-resveratrol,
genistein, daidzein, apigenin) in Me2SO (3 mg ml71) were
prepared and stored at 7208C. Just before each experiment
aliquots were thawed and diluted with Me2SO up to a
desirable concentration (see speci®c ®gure legends). Stock
solutions of phytoestrogens were diluted 200 fold into the
spectro¯uorometric cuvette to give the desired ®nal
concentration.

Figure 2 Eect of trans-resveratrol on [Ca2+]i in thrombinstimulated platelets. Calcium 2 mM was added to the platelet
suspension 20 s before data collection started (zero time). Ten
seconds later, trans-resveratrol solution was added to yield a ®nal
concentration in the platelet suspension of either 0.1, 1.0 or 10 mM.
Thrombin (0.01 u ml71) was added 10 s later. Thrombin caused a
large increase in [Ca2+]i in the control condition, platelets started to
aggregate at 60 ± 80 s. All three concentrations of trans-resveratrol
inhibited the thrombin-induced rise in [Ca2+]i in a dose-dependent
manner. The trace shown is from a representative experiment; similar
results were obtained from six other platelet preparations and are
presented in Figure 3.

Figure 3 Dose-response of trans-resveratrol to inhibit thrombininduced elevation of [Ca2+]i and Ba2+ ion in¯ux. The % inhibitory
eect of trans-resveratrol was calculated by subtracting the basal or
pre-stimulated value from the peak eect with trans-resveratrol
present and comparing it to the eect observed in the control with
thrombin and without trans-resveratrol. The IC50 was 0.5 mM for
both parameters, and was calculated by estimating the concentration
of trans-resveratrol that produced 50% inhibition of the maximum
inhibitory eect which was 57% inhibition of the [Ca2+]i response,
and 50% inhibition of the barium ion in¯ux response. These values
were 28.5% for [Ca2+]i (i.e. 1/2 of 57%) and 25% for barium ion
in¯ux (i.e. 1/2 of 50%). The data represent mean+s.e.mean from six
separate experiments with dierent platelet donors, typical experiments are shown in Figures 2 and 7. Statistical signi®cance of transresveratrol eect when compared to thrombin control: *P50.05,
**P50.01.
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ARCM spectro¯uorometer using excitation wavelengths of
340 and 380 nm and an emission wavelength of 505 nm.
Calibration was performed as previously described for human
sperm (Blackmore et al., 1990). [Ca2+]i was calculated by using
the SPEX dM3000 software package.

Measurement of [Ba

2+

]i

To assess basal Ca2+ channel activity without agonist
stimulation, Ba2+ was added to platelets in Ca2+-free medium
to act as a calcium surrogate. Ba2+ enters the cell through
Ca2+ channels, but unlike Ca2+, it cannot be extruded from
the cell by plasma membrane Ca2+-ATPase pump therefore it
accumulates in the cell (Ozaki et al., 1992; Zschauer et al.,
1988; Blache & Clavatti, 1987; Blache et al., 1887). The
removal of Ba2+ from the cytoplasm by the endoplasmic
reticulum may be limited when compared to Ca2+ and Sr2+
(Ozaki et al., 1992). When Ca2+ enters the cell through plasma
membrane calcium channels it can be either extruded from the
cell by the Ca2+-ATPase pump or sequestered within
organelles such as the endoplasmic reticulum and mitochondria Therefore when Ca2+ is added to platelets suspended in
low Ca2+ containing medium the [Ca2+]i changes very little.
Once inside the cell, Ba2+ forms a ¯uorescent complex with the
dye fura-2, in a similar manner to Ca2+, but with a dierent
anity (KD=1360 nM for Ba2+ and KD=227 nM for Ca2+,
Ozaki et al., 1992). The intensity of the ¯uorescence is directly
proportional to the [Ba2+]i. BaCl2 (5 mM) was added to the
fura-2 loaded platelets in the absence of Ca2+ and in the
absence of agonist. The fura-2/Ba2+ ¯uorescent complex was
determined by measuring the 340/380 nm ¯uorescence ratio.
The addition of thrombin with Ba2+ causes a large increase in
340/380 nm ratio, consistent with thrombin stimulating Ba2+
in¯ux through SOCC. However it was not possible to
determine how much of the ¯uorescence increase was due to

Figure 4 trans-Resveratrol does not aect [Ca2+]i level in platelets
in the absence of thrombin stimulation. All experiments were
performed in the presence of 2.0 mM external calcium. Thrombin
control experiment represents [Ca2+]i elevation in platelets, stimulated with thrombin alone (0.01 u ml71). trans-Resveratrol 10 mM
signi®cantly inhibited thrombin response, similar to data shown in
Figure 2. trans-Resveratrol 10 mM, by itself did not in¯uence [Ca2+]i.
The trace shown is from a representative experiment; similar results
were obtained from six other platelet preparations.

trans-Resveratrol inhibits platelet Ca2+ influx

Ba2+ and how much was due to Ca2+ being mobilized from
intracellular stores, although mobilization of Ca2+ from
intracellular Ca2+ stores only produces a small increase in
[Ca2+]i (compare Figures 4 and 5).

Thapsigargin-induced [Ca2+]i entry
After Ca2+ was added back to the platelet suspensions,
thapsigargin (dissolved in Me2SO) was added to the platelet
suspension to a ®nal concentration of 1077 M and the
¯uorescence was monitored as described previously.

Statistical analysis
Data are reported as mean+s.e.mean for the number of
individual experiments speci®ed in the Figure legends.
Comparisons were made using Student's t-test, with a P value
50.05 considered signi®cant. Dierent platelet donors were
used for each experiment.

Results
Eects of trans-resveratrol on thrombin-induced [Ca2+]i
increase in human platelets
Treatment of the platelet suspension with trans-resveratrol
markedly reduced the elevation of the [Ca2+]i in response to
the thrombin. The data in Figure 2 shows a representative
experiment in which three dierent concentrations of trans-

Figure 5 Eect of trans-resveratrol on the release of the internally
stored calcium in thrombin stimulated platelets. External calcium was
not added to the platelet suspension, 5 mM EGTA was also added
20 s prior to data collection (zero time). Thrombin (0.01 u ml71)
caused a very small increase in [Ca2+]i when calcium was removed
from the external medium, compare to data in Figure 4. transResveratrol 10 mM produced a small inhibition of thrombin to
mobilize internal calcium, although the inhibitory eect was not
statistically signi®cant (see text for actual values). The data in Figure
5 (no calcium plus EGTA) is directly comparable to the data shown
in Figure 4 (with 2.0 mM calcium) since the same platelet preparation
was used in both experiments. The trace shown is from a
representative experiment; similar results were obtained from three
other platelet preparations.
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resveratrol were added to platelets. The eect of transresveratrol was observed after a short 5 ± 10 s incubation with
trans-resveratrol before adding thrombin. It takes 5 ± 10 s for
complete mixing of the 2.5 ml aliquot of the trans-resveratrol
solution in the 500 ml aliquot of platelet suspension in the
spectro¯uorometric cuvette using a magnetic stirrer bar. transResveratrol reduced both the rate of [Ca2+]i rise together with
the peak level of [Ca2+]i induced by thrombin. The data in
Figure 3 is an average of six experiments, similar to that shown
in Figure 1, and shows that trans-resveratrol produced a dosedependent inhibition of the [Ca2+]i increase with an IC50 of
0.5 mM, see Figure 3 legend for details. The data shows that
0.1, 1.0 and 10.0 mM trans-resveratrol produced statistically
signi®cant inhibitory eects of 20+6% (P50.01), 37+6%
(P50.001) and 57+4% (P50.001). The maximum degree of
inhibition (57+4%) was observed with 10 mM trans-resveratrol, higher concentrations of trans-resveratrol were not used
because they caused large changes in ¯uorescence that
interfered with the fura-2 ¯uorescence measurements (data
not shown). Cholesterol (negative control steroid) at a
concentration of 10 mM, and the Me2SO solvent (0.5%
v v71) used to dissolve trans-resveratrol did not in¯uence
[Ca2+]i levels (data are not shown). trans-Resveratrol did not
interfere with the calcium ionophore ionomycin (10.0 mM) or
digitonin (0.01%) induced [Ca2+]i elevations in human
platelets, thereby demonstrating that trans-resveratrol does
not in¯uence fura-2 ¯uorescence and therefore rules out any
non-speci®c eects of the phytoestrogen on the [Ca2+]i
measurements. Both these agents increase [Ca2+]i by mechanisms independent of plasma membrane calcium channels.
The data in Figure 4 depicts a representative experiment
that indicates trans-resveratrol alone did not have an eect on
[Ca2+]i level in the absence of thrombin stimulation. In the
same experiment trans-resveratrol blocked the thrombin eect
similar to that shown in Figure 2, although in this particular
experiment the inhibitory eect was larger. The elevation of

Figure 6 Dose response of extracellular calcium on the ability of
thrombin to increase [Ca2+]i in the presence and absence of transresveratrol. Various concentrations of calcium were added to the
medium 20 s before data collection was started (zero time). Thrombin
0.01 u ml71 was then added to the platelets in the presence and
absence of 10 mM trans-resveratrol as described in the legend to
Figure 2. The data shown is the mean+s.e.mean from three separate
experiments.*P40.05, **P50.05.
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[Ca2+]i in thrombin stimulated platelets, without the addition
of Ca2+ to the medium together with 5.0 mM EGTA added to
the buer, was substantially smaller (25 nM increase, Figure 5),
compared with [Ca2+]i elevation in the presence of the external
Ca2+ (500 nM increase, Figure 4). The elevation of [Ca2+]i
induced by thrombin in EGTA containing media was 7+2%
of that seen in the presence of 2.0 mM calcium (average from
three separate experiments). This suggested that the majority
of the [Ca2+]i increase, due to thrombin (0.01 u ml71)
stimulation, was primarily due to Ca2+ in¯ux, and not the
result of the emptying of the internal Ca2+ stores. The data in
Figure 5 showed that 10 mM trans-resveratrol produced a very
small inhibition of the thrombin-induced internal mobilization
of calcium. The average of four separate experiments showed
that 10.0, 1.0 and 0.1 mM trans-resveratrol produced an 8+10,
2+11 and 12+11% inhibition respectively of thrombin, these
small inhibitory eects were not statistically signi®cant
(P40.05).
Extracellular calcium in the concentration range of 50 ±
4000 mM did not overcome the trans-resveratrol inhibition of
Ca2+ in¯ux into the thrombin-stimulated platelets (Figure 6).
The eect of trans-resveratrol to inhibit thrombin-induced
increases in [Ca2+]i was very small (not statistically signi®cant,
P40.05) when the extracellular calcium was in the 50 ± 250 mM
range. This is consistent with the data shown in Figure 5 in
which trans-resveratrol produced a small but not statistically
signi®cant inhibition (see above) of thrombin in the presence of
extracellular EGTA and no added calcium. When the
extracellular calcium was increased to 500 ± 4000 mM, thrombin was then able to promote a much larger increase in [Ca2+]i
due to a greater calcium in¯ux and the eect of trans-

Figure 7 Eect of thapsigargin and trans-resveratrol on Ba2+ ion
in¯ux into platelets in calcium-free medium. Control represents the
experiment where 5.0 mM Ba2+ was added alone to the platelet
suspension. trans-Resveratrol concentrations 10, 1.0 and 0.1 mM
inhibited basal Ba2+ in¯ux into platelets. Results are expressed as
340/380 ¯uorescence ratios. Thapsigargin 1077 M stimulated Ba2+
ion in¯ux over control levels. When no calcium or Ba2+ was added,
thapsigargin 1077 M produced a small elevation in [Ca2+]i as
indicated by a small increase in the 340/380 nm ratio. The trace
shown is from a representative experiment, similar results were
obtained from six other platelet preparations. The dose response of
trans-resveratrol to inhibit Ba2+ in¯ux into platelets is shown in
Figure 3.
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resveratrol was much more pronounced (Figures 4 and 6). The
degree of inhibition induced by trans-resveratrol remained
constant as the Ca2+ concentration increased in the 1000 ±
4000 mM range (Figure 6).

Eect of trans-resveratrol on the basal Ca2+ channel
activity measured by monitoring Ba2+ uptake
Non-stimulated (control) platelets exhibit a biphasic (an early
and a late component) rise in Ba2+ possibly due to at least two
dierent populations of Ca2+ channels, which are accessible
for Ba2+ entry (Figure 7). In most of the experiments the in¯ux
of Ba2+ began to induce platelet aggregation after 2 min. The
rational for examining basal Ba2+ in¯ux in the absence of
thrombin was that the in¯uence of various second messenger
pathways (e.g. tyrosine phosphorylation, Ca2+ store depletion,
cyclic nucleotides) would not be involved and hence the eect
of the various phytoestrogens would only be on the Ca2+
in¯ux channels and not on any agonist stimulated signal
transduction pathway(s). trans-Resveratrol produced a large
inhibition of Ba2+ in¯ux into the platelets, aecting mostly the
later component of entry. Three dierent concentrations (0.1,
1.0 and 1.0 mM) of trans-resveratrol are shown in this
representative experiment (Figure 7). The dose-response of
trans-resveratrol to inhibit Ba2+ in¯ux from six dierent
experiments is shown in Figure 3, with 0.1, 1.0 and 10.0 mM
trans-resveratrol producing 10+5 (P50.05), 30+5 (P50.01)
and 50+7% (P50.01) inhibition respectively. Thapsigargin
stimulated Ba2+ in¯ux, both the rate of in¯ux and the
magnitude of the in¯ux (Figure 7). This result shows that at
least some of the Ba2+ that enters the platelet is through SOCC
(see also Figure 8). When thapsigargin was added to platelets

2+

Figure 8 Eect of trans-resveratrol on thapsigargin-induced [Ca ]i
in platelets. Experiments were conducted in the presence of 2.0 mM
external calcium. The control trace represents the [Ca2+]i increase in
platelets stimulated with thapsigargin 1077 M alone. trans-Resveratrol concentrations of 0.1, 1.0, and 10 mM dramatically decreased the
rate of [Ca2+]i increase in thapsigargin-exposed platelets. The trace
shown is from a representative experiment, similar results were
obtained in seven other platelet preparations. trans-Resveratrol, 0.1,
1.0 and 10.0 mM, increased the time to reach the EC50 for maximum
[Ca2+]i elevation by 20+6, 30+7 and 94+10% respectively.

trans-Resveratrol inhibits platelet Ca2+ influx

in the absence of both calcium and Ba2+ there was a small
increase in the 340/380 nm ratio (Figure 7). This result
demonstrates that thapsigargin was able to mobilize intracellular calcium stores and that these stores were relatively small
in platelets. This result is consistent with the data in Figures 4
and 5 in which chelation of extracellular calcium with EGTA
reduced the ability of thrombin to increase [Ca2+]i by 93%.
Even though thapsigargin only produced a small mobilization
of intracellular calcium, it was sucient to promote a large
Ba2+ ion in¯ux through SOCC (Figure 7).

Eect of trans-resveratrol on thapsigargin-induced Ca2+
entry
trans-Resveratrol markedly decreased, in a dose-dependent
manner, thapsigargin-induced Ca2+ in¯ux, which suggested
that SOCC are one of the possible targets for trans-resveratrol
in the platelets (Figure 8). This result is consistent with the data
on Ba2+ in¯ux shown in Figure 7. Thapsigargin produced a
delayed response to increase [Ca2+]i, compared to that seen
with thrombin (also see Figure 2), with [Ca2+]i values reaching
1 mM, approximately 100 s after stimulation. In most of the
experiments, even though the trans-resveratrol inhibited the
rate of increase in [Ca2+]i and delayed the onset of the increase
in [Ca2+]i, the increase in [Ca2+]i eventually approached that
obtained in the control. We therefore expressed the inhibition
data as the time to reach the half maximum [Ca2+]i value
(EC50) for the thapsigargin control. The basal [Ca2+]i value
was subtracted from the maximum [Ca2+]i value obtained in
each run, this number was divided by 2, then this number was
added to the basal value. The time it takes to reach this 50%

Figure 9 Eect of phytoestrogens genistein, daidzein and apigenin
on [Ca2+]i level in thrombin-stimulated platelets. Calcium was added
to the platelet suspension to a concentration of 2.0 mM 20 s before
data collection was started (zero time). Approximately 10 s later,
either genistein, daidzein or apigenin was added to yield ®nal
concentrations in the platelet suspension of 10 mM. Thrombin
(0.01 u ml71) was added approximately 10 s later. All three
phytoestrogenic compounds inhibited the thrombin-induced rise in
[Ca2+]i in a similar manner to that seen with trans-resveratrol
(Figures 2, 3 and 4). The trace shown is from a representative
experiment; similar results were obtained from four other platelet
preparations.
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value, after thapsigargin addition with various concentrations
of trans-resveratrol, was the time to reach the EC50. To
normalize each experiment we expressed the data as %
increase in time over the control. Therefore when 0.1, 1.0 and
10.0 mM trans-resveratrol was added the time for thapsigargin
to reach the EC50 was 20+6 (P50.01), 30+7 (P50.01) and
94+10% (P50.001), data from seven separate experiments.
This data shows that the greater the inhibition by transresveratrol the greater the % increase in time to reach the EC50.

Eect of other phytoestrogens on the thrombin-induced
[Ca2+]i increase in human platelets
The phytoestrogens apigenin, daidzein, genistein, (Figure 1) as
well as genistein-glycoside did not cause a change in the [Ca2+]i
when added to non-stimulated platelet suspension, similar to
that observed with trans-resveratrol (Figure 4). All the above
compounds caused a marked decrease in [Ca2+]i, in thrombinstimulated platelets (Figure 9). Daidzein (10 mM) produced a
42+4% inhibition of thrombin, average from four experiments, genistein (10 mM) produced a 50+5% inhibition of
thrombin, average from seven experiments and in three
separate experiments 10 mM apigenin produced a 50+8%
inhibition of thrombin. The degree of the inhibition produced
by each phytoestrogen was similar to the inhibition caused by
10 mM trans-resveratrol, which was 57+4% (see Figures 2 and
3). The IC50 was 1 mM for each phytoestrogen tested.
The very rapid inhibitory action of apigenin, daidzein, and
genistein (immediately upon contact with platelets) suggested
that these compounds produced their eects on the platelet
surface. To con®rm this suggestion, the addition of hydrophilic

Figure 10 Genistein-7-D-glucoside inhibited calcium in¯ux into
thrombin-stimulated platelets in a manner similar to that of genistein.
Calcium was added to the platelet suspension to a concentration of
2.0 mM 20 s before data collection starts (zero time). Approximately
5 s later, either genistein or genistein-7-D-glucoside was added to
yield ®nal concentration in the platelet suspension of 10 mM.
Thrombin (0.01 u ml71) was added at approximately 10 s after data
collection started. No phytoestrogens were added to the platelets in
the thrombin control experiment. Both compounds inhibited the
thrombin-induced rise in [Ca2+]i in a similar manner. The trace
shown is from a representative experiment; similar results were
obtained from three other platelet preparations.
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conjugates of these compounds should produce a similar
inhibitory eect, since they are unlikely to be able to traverse
the hydrophobic plasma membrane and hence will be con®ned
to the extracellular space. One such analogue was commercially available, namely genistein-7-O-D-glucoside (4',5,7trihydroxyiso¯avone-7-glucoside). The data in Figure 10
shows that genistein-7-O-D-glucoside produced an inhibitory
eect similar to that of genistein, which implied that the eect
was mediated by genistein-7-O-D-glucoside acting on the
platelet surface and not on some intracellular target.
Genistein-glucoside (10 mM) produced a 37+6% inhibition of
thrombin in three separate experiments, while genistein
(10 mM) produced a 50+5% inhibition of thrombin in seven
separate experiments. The inhibitory eects of both agents
were not signi®cantly dierent from each other.

Discussion
The inhibitory eect of trans-resveratrol on platelet aggregation has been described (Pace-Asciak et al., 1995; 1996; Bertelli
et al., 1995). However, little is known about the actual
mechanism of this phenomena. The present study demonstrates for the ®rst time that trans-resveratrol signi®cantly
inhibited Ca2+ in¯ux into thrombin-stimulated platelets. Since
a rise in the [Ca2+]i is a necessary step for aggregation, we
suggest that the Ca2+ blocking action of trans-resveratrol was
responsible for the observed inhibition of thrombin induced
platelet aggregation in platelet rich plasma (Pace-Asciak et al.,
1995; 1996; Bertelli et al., 1995), which we have also con®rmed
using washed human platelets. The mode of inhibition was
very rapid (several seconds preincubation), essentially at the
moment of contact with the platelets. Incubating the platelets
for longer periods (up to 120 min) with trans-resveratrol did
not produce any further inhibitory eect (data not shown).
Studies performed in polymorphonuclear leukocytes (PMN)
demonstrated that trans-resveratrol was able to inhibit formyl
methionyl leucyl phenylalanine (fMLP) induced elevations of
[Ca2+]i (Rotondo et al., 1998). The PMN's do not appear to be
as responsive to trans-resveratrol as the platelets are in our
present study. The rise in [Ca2+]i in the PMN's was inhibited
slightly by 22 mM trans-resveratrol, with near maximum
inhibition seen with 110 mM trans-resveratrol (Rotondo et al.,
1998). The elevation of [Ca2+]i in platelets induced by
thrombin was seen with as little as 0.1 mM trans-resveratrol,
with a maximum 57+4% inhibition seen with 10 mM transresveratrol (Figure 3). We did not use amounts of transresveratrol higher than 10 mM due to its insolubility at higher
concentrations, and the quenching of the fura-2 ¯uorescence.
The question remains whether trans-resveratrol acts
immediately on the platelet Ca2+ channels or whether
inhibition of Ca2+ in¯ux is a secondary phenomenon to some
other unknown primary eect of trans-resveratrol. It is
possible that trans-resveratrol and other phytoestrogens
generate an inhibitory second messenger to block calcium
in¯ux, such as cyclic AMP or cyclic GMP (Sage, 1997).
However, the ®nding that trans-resveratrol inhibited the basal
activity of Ca2+ channels, measured by measuring Ba2+ ion
in¯ux in non-stimulated platelets, suggested that transresveratrol may have a binding site on the cell surface, thus
directly aecting the channel itself. The ®rst component of
Ba2+ entry seems to remain unaected by trans-resveratrol,
however the second component was inhibited dramatically. An
IC50 of 0.5 mM was estimated for trans-resveratrol to block
Ba2+ in¯ux (Figure 3). The phenomena, where transresveratrol immediately inhibited Ba2+ in¯ux into platelets,

156

Y. Dobrydneva et al

supports the hypothesis that ionic channels are involved. Since
basal Ba2+ in¯ux is independent from the generation of second
messengers (no agonist used), trans-resveratrol probably acts
on the channel directly.
The apparent target for trans-resveratrol action seems to be
the SOCC, since thapsigargin mediated increases in [Ca2+]i are
also inhibited by trans-resveratrol (Figure 8). This is consistent
with the fact that thrombin stimulated Ca2+ in¯ux is primarily
through the SOCC. Experiments also suggested that transresveratrol was unable to inhibit thrombin induced release of
intracellular stored Ca2+ (Figure 5), although a very small, not
statistically signi®cant, inhibition was observed. Though it
appears that trans-resveratrol acts on the platelet surface, there
is still a possibility that a very small inhibition of internal Ca2+
release may translate into an inhibition of the plasma
membrane Ca2+ channels, since the Ca2+ in¯ux process
through SOCC depends on the degree of ®lling of the internal
Ca2+ stores (Parekh & Penner, 1997). The data in Figure 6
suggests that trans-resveratrol and Ca2+ are not competing for
the same site on the calcium channel, since the transresveratrol inhibition of thrombin induced elevation of [Ca2+]i
could not be overcome by increasing the extracellular Ca2+.
Other types of phytoestrogens (apigenin, daidzein, genistein, genistein-glucoside) showed a similar mode of action to
trans-resveratrol on thrombin-stimulated platelets, by inhibiting Ca2+ in¯ux. Genistein-glucoside, being a very hydrophilic
compound, is a tool to explore indirectly if the phytoestrogens
have their primary targets on the platelet surface rather than
on an intracellular target. Genistein and genistein-glucoside
have a very similar time course of action, inhibiting Ca2+
in¯ux apparently at the moment of their contact with the
platelet (Figure 10). This evidence also indirectly supports the
hypothesis that phytoestrogens act upon the platelet surface,
directly or indirectly changing Ca2+ channel activity.
The key point to resolve is whether trans-resveratrol and
other phytoestrogens act directly on the cell surface or must
penetrate the inside of the platelet. This could be clari®ed by a
direct radiolabelled ligand binding and anity labelling
experiment to platelet membranes. It would be of interest to
explore what intracellular signal transduction pathways are
involved in the trans-resveratrol action. Examining whether
trans-resveratrol and other phytoestrogens change the phosphorylation state of the intracellular targets would be
important since several phytoestrogens have been shown to
act as tyrosine kinase inhibitors, although high concentrations
are required to inhibit a variety of kinases. For genistein the
IC50 for the epidermal growth factor receptor tyrosine kinase is
2.6 mM, for p60v-src the IC50=25 mM and for protein kinase C
and protein kinase A the IC504100 mM (Akiyama et al., 1987).
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In our experiments we observed inhibition of thrombin eects
by genistein and the other phytoestrogens daidzein, apigenin
and trans-resveratrol in the 0.1 ± 10 mM concentration range
(Figure 9 and data not shown). Since daidzein is used as an
inactive analogue of genistein in tyrosine kinase experiments
(Akiyama et al., 1987), and since both daidzein and genistein
produced the same degree of inhibition of thrombin (Figure 9)
this would argue against these compounds producing the
inhibition of Ca2+ in¯ux in platelets by inhibiting a tyrosine
kinase.
The levels of trans-resveratrol in red wine are typically in the
10 ± 100 mM (0.4 ± 4 mg l71) range (Soleas et al., 1997), with
wine from Cabernet Savignon having levels as high as 7 mg l71.
Also the presence of trans-resveratrol-glucoside (piceid) in wine
may also contribute to the levels of trans-resveratrol in the
blood. Even though much experimental data supports the
biological activity of trans-resveratrol in vivo, following regular
wine consumption in man (e.g. Tham et al., 1998), no serum
levels have been reported. Also there is no data on clearance
from the blood and ®rst-pass eects in the portal circulation of
the liver (e.g. Gehm et al., 1997). The data presented by PaceAsciak et al. (1996), in which humans had consumed 2 mg of
trans-resveratrol per day, showing decreased platelet activity
was very convincing. This amount of trans-resveratrol is
equivalent to consuming approximately 1 L of a typical red
wine per day (Soleas et al., 1997). We observed that genistein
and genistein-glucoside (Figures 9 and 10) were able to inhibit
thrombin induced elevations of [Ca2+]i similar to that seen with
trans-resveratrol (Figures 2 and 3). After consuming a soybean
¯our-based meal on two occasions, 6 days apart, the levels of
genistein and daidzein reached peak plasma levels of 4 and
3 mM respectively, with elimination half-lives of 5.7 and 4.7 h,
respectively (King & Bursill, 1998). These levels of genistein
and daidzein were able to inhibit the ability of thrombin to
elevate [Ca2+]i in platelets in vitro (Figure 9). In another study
involving 14 Japanese men, average age 55 years on an
uncontrolled diet, the plasma phytoestrogen levels were
approximately 0.4 mM (Adlercreutz et al., 1993).
In conclusion, since phytoestrogenic compounds are present
in a variety of foods (Mikscicek, 1995), their Ca2+-channels
blocking action may be potentially bene®cial in the prevention
and management of cardiovascular disease and other
cardiovascular dysfunctions in which thrombosis plays a role.
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